Here are the most recent widely reported results for retatrutide (Eli Lilly’s investigational “triple-agonist” obesity drug) and what they mean for weight-loss outcomes.
Latest weight-loss results (recent reports)
- Phase 3 (68 weeks) in obesity + knee osteoarthritis (TRIUMPH-4): Reported weight loss was 28.7% for participants on the highest dose who stayed on treatment, and 23.7% when looking across all treated participants (including those who discontinued).[1]
- Coverage also emphasizes that side effects were common and many participants stopped the drug, including people who felt they were losing too much weight.[1]
- Another recent news report (based on Lilly’s release) says patients saw about 70.3 pounds lost over 80 weeks, with 45% on the 12 mg dose losing up to 30% of body weight.[4]
Quick context: why it’s different from current GLP-1s
Retatrutide is described as targeting three hormone receptors—GIP, GLP-1, and glucagon—which is why it’s often called a “triple agonist.”[4]
Important caveat
Because retatrutide is still investigational, results come from clinical trials, and you should not interpret headline weight-loss percentages as guaranteed outcomes for individuals—especially given the reported tolerability/discontinuation issues in recent Phase 3 reporting.[1]
If you tell me your goal (e.g., “best numbers for maximum dose,” “safety/tolerability highlights,” or “how it compares to Wegovy/Zepbound”), I can summarize the latest findings in that specific frame.
Sources
Eli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too much weight.
www.statnews.comThe company’s triple-acting drug retatrutide helped Phase 2 study participants lose a quarter of their body weight, more than what’s been observed in testing of other medicines.
www.biopharmadive.comTransformation videos highlighting crazy weight loss journeys are taking over social media.
www.cbsnews.comParticipants of a phase III trial of investigational weight-loss drug retatrutide showed an average weight loss of almost 30% and “substantial” relief from knee osteoarthritis, manufacturer Eli Lilly and Company has announced. In a statement published on 11 December 2025, Eli Lilly reported results from its TRIUMPH-4 trial, which involved 445 participants aged over 18 […]
pharmaceutical-journal.comA new weight loss injection called retatrutide has shown remarkable results in…
www.diabetes.co.ukFindings demonstrated that participants with obesity lost more than 24% of their starting body weight within 48 weeks of treatment with the highest dose of retatrutide. Additionally, 100% of the participants taking either of the two higher doses (8 mg and 12 mg) lost at least 5% or more of their body weight. The results indicate that retatrutide has an overall safety and tolerability profile similar to other nutrient-stimulated hormone-based therapies, such as GLP-1 receptor agonists approved...
diabetes.org(UPDATED) The once-weekly injectable targeting three hormone receptors hints at “fundamental change” for cardiometabolic disease.
www.tctmd.com"Retatrutide delivered powerful weight loss," Leerink Partners analyst David Risinger told investors on Thursday morning. The study's results are the latest signal that retatrutide may be the most effective weight-loss medication in development. As such, retatrutide is a highly anticipated addition to Lilly's (LLY) obesity portfolio, which already includes Zepbound, a weekly GLP-1/GIP shot, and Foundayo, a daily non-peptide GLP-1 pill. It is sometimes referred to as "triple G" because it...
www.morningstar.comThe results of the drug are comparable to what is seen with bariatric surgery, according to Eli Lilly.
abcnews.com